Transient but transformative: Sanofi's mRNA CAR-T enters in vivo race [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
the body, bypassing the weeks-long ex vivo manufacturing required for ex vivo CAR-Ts. The platform uses mRNA to instruct the cell to produce the chimeric antigen receptor (CAR), resulting in transient CAR expression. The company has heavily invested in developing the technology. In August 2021, Sanofi acquired Translate Bio for $3.2bn, gaining full access to its large library of lipid nanoparticles (LNPs). These fat-based particles shield the mRNA in the bloodstream. A challenge in administering LNPs is that they naturally accumulate in the liver, where they are filtered. Realising this, Sanofi acquired Tidal Therapeutics in April 2021 for $470m. With this purchase, Sanofi can leverage Tidal's VHH nanobody-based technology, which selectively binds to CD8 on cytotoxic T cells, enhancing tumour cell targeting and transfection efficiency. A non-viral targeted LNP represents an innovative approach for in vivo CAR-T programs. In a preclinical mouse model, LN15 was optimised for T-cell tr
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (SNY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]Yahoo! Finance
- Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoire [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoireGlobeNewswire
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website